Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Operating Margin (2016 - 2025)

Ptc Therapeutics has reported Operating Margin over the past 14 years, most recently at 43.33% for Q4 2025.

  • Quarterly results put Operating Margin at 43.33% for Q4 2025, up 3285.0% from a year ago — trailing twelve months through Dec 2025 was 50.09% (up 9889.0% YoY), and the annual figure for FY2025 was 50.09%, up 8760.0%.
  • Operating Margin for Q4 2025 was 43.33% at Ptc Therapeutics, down from 1.43% in the prior quarter.
  • Over the last five years, Operating Margin for PTCT hit a ceiling of 82.5% in Q1 2025 and a floor of 119.67% in Q4 2022.
  • Median Operating Margin over the past 5 years was 53.37% (2023), compared with a mean of 45.53%.
  • Biggest five-year swings in Operating Margin: surged 16449bps in 2021 and later tumbled -7807bps in 2024.
  • Ptc Therapeutics' Operating Margin stood at 51.28% in 2021, then crashed by -133bps to 119.67% in 2022, then soared by 102bps to 1.9% in 2023, then crashed by -4119bps to 76.18% in 2024, then soared by 43bps to 43.33% in 2025.
  • The last three reported values for Operating Margin were 43.33% (Q4 2025), 1.43% (Q3 2025), and 19.54% (Q2 2025) per Business Quant data.